344 related articles for article (PubMed ID: 24837745)
1. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Bishop C
Behav Brain Res; 2014 Aug; 270():75-85. PubMed ID: 24837745
[TBL] [Abstract][Full Text] [Related]
2. Striatal norepinephrine efflux in l-DOPA-induced dyskinesia.
Ostock CY; Bhide N; Goldenberg AA; George JA; Bishop C
Neurochem Int; 2018 Mar; 114():85-98. PubMed ID: 29371053
[TBL] [Abstract][Full Text] [Related]
3. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
4. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Barnum CJ; Bhide N; Lindenbach D; Surrena MA; Goldenberg AA; Tignor S; Klioueva A; Walters H; Bishop C
Pharmacol Biochem Behav; 2012 Jan; 100(3):607-15. PubMed ID: 21978941
[TBL] [Abstract][Full Text] [Related]
5. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
[TBL] [Abstract][Full Text] [Related]
6. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
Holden H; Venkatesh S; Budrow C; Nezaria S; Coyle M; Centner A; Lipari N; McManus G; Bishop C
Physiol Behav; 2024 Jul; 281():114563. PubMed ID: 38723388
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Winkler C; Kirik D; Björklund A; Cenci MA
Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
[TBL] [Abstract][Full Text] [Related]
8. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
9. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
[TBL] [Abstract][Full Text] [Related]
10. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
11. Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.
Bhide N; Lindenbach D; Barnum CJ; George JA; Surrena MA; Bishop C
J Neurochem; 2015 Jul; 134(2):222-32. PubMed ID: 25866285
[TBL] [Abstract][Full Text] [Related]
12. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Lindenbach D; Ostock CY; Eskow Jaunarajs KL; Dupre KB; Barnum CJ; Bhide N; Bishop C
J Pharmacol Exp Ther; 2011 Jun; 337(3):755-65. PubMed ID: 21402691
[TBL] [Abstract][Full Text] [Related]
14. Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Ostock CY; Hallmark J; Palumbo N; Bhide N; Conti M; George JA; Bishop C
Neuropharmacology; 2015 Aug; 95():215-25. PubMed ID: 25817388
[TBL] [Abstract][Full Text] [Related]
15. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Chagniel L; Robitaille C; Lebel M; Cyr M
Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
17. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Eskow Jaunarajs KL; George JA; Bishop C
Neuroscience; 2012 Aug; 218():243-56. PubMed ID: 22659568
[TBL] [Abstract][Full Text] [Related]
18. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
Chotibut T; Apple DM; Jefferis R; Salvatore MF
PLoS One; 2012; 7(12):e52322. PubMed ID: 23300642
[TBL] [Abstract][Full Text] [Related]
19. Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
Conti MM; Goldenberg AA; Kuberka A; Mohamed M; Eissa S; Lindenbach D; Bishop C
Pharmacol Biochem Behav; 2016 Mar; 142():64-71. PubMed ID: 26791104
[TBL] [Abstract][Full Text] [Related]
20. Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Chambers NE; Coyle M; Sergio J; Lanza K; Saito C; Topping B; Clark SD; Bishop C
Eur J Neurosci; 2021 Apr; 53(8):2835-2847. PubMed ID: 33426708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
